{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:21:42Z","timestamp":1767997302162,"version":"3.49.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":105,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001342","name":"South Africa Department of Science and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mutation Research - Reviews in Mutation Research"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.mrrev.2024.108492","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T15:49:07Z","timestamp":1713196147000},"page":"108492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Incorporating functional genomics into the pathology-supported genetic testing framework implemented in South Africa: A future view of precision medicine for breast carcinomas"],"prefix":"10.1016","volume":"793","author":[{"given":"Claudia","family":"Christowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel W.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann W.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maritha J.","family":"Kotze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Mart","family":"Engelbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mrrev.2024.108492_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.mrrev.2024.108492_bib2","series-title":"Breast tumours","year":"2019"},{"key":"10.1016\/j.mrrev.2024.108492_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12920-016-0183-8","article-title":"Building towards precision medicine: empowering medical professionals for the next revolution","volume":"9","author":"McGrath","year":"2016","journal-title":"BMC Med. Genom."},{"key":"10.1016\/j.mrrev.2024.108492_bib4","unstructured":"AESA, A Framework for the Implementation of Genomic Medicine for Public Health in Africa, 2020."},{"key":"10.1016\/j.mrrev.2024.108492_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2022.769919","article-title":"A view on genomic medicine activities in Africa: implications for policy","volume":"13","author":"Jongeneel","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.mrrev.2024.108492_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/pme.13.43","article-title":"Pathology-supported genetic testing directed at shared disease pathways for optimized health in later life","volume":"10","author":"Kotze","year":"2013","journal-title":"Per. Med."},{"key":"10.1016\/j.mrrev.2024.108492_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/14737159.2023.2203815","article-title":"Pathology-supported genetic testing for the application of breast cancer pharmacodiagnostics: family counselling, lifestyle adjustments and change of medication","volume":"23","author":"Okunola","year":"2023","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.mrrev.2024.108492_bib8","unstructured":"M.J. Kotze, Personalised Medicine - From Vision to Practice: A pathology-supported genetic testing platform for application of breast cancer pharmacogenetics at the point-of-care using an integrated service and research approach., in: 2nd ICPerMed Conf., ICPerMed, Paris, France, 2021. \u3008https:\/\/www.icpermed.eu\/en\/798.php\u3009."},{"key":"10.1016\/j.mrrev.2024.108492_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2020.00170","article-title":"Pioneering informed consent for return of research results to breast cancer patients facing barriers to implementation of genomic medicine: the Kenyan BRCA1\/2 testing experience using whole exome sequencing","volume":"11","author":"Torrorey-Sawe","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.mrrev.2024.108492_bib10","first-page":"S754","article-title":"Translating population risk into personal utility using a mobile phone app for application of genomic medicine integrating service and research in the covid-19 era","author":"Kotze","year":"2023","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.mrrev.2024.108492_bib11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/10408363.2014.997930","article-title":"Genomic medicine and risk prediction across the disease spectrum","volume":"52","author":"Kotze","year":"2015","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.mrrev.2024.108492_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103174","article-title":"Breast cancer, screening and diagnostic tools: all you need to know","volume":"157","author":"Barba","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.mrrev.2024.108492_bib13","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1200\/JCO.2016.70.3959","article-title":"Impact of 70-gene signature use on adjuvant chemotherapy decisions in patients with estrogen receptor\u2013positive early breast cancer: results of a prospective cohort study","volume":"35","author":"Kuijer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mrrev.2024.108492_bib14","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-023-14027-9","article-title":"The predictive Utility of MammaPrint and BluePrint in identifying patients with locally advanced breast cancer who are most likely to have nodal downstaging and a pathologic complete response after neoadjuvant chemotherapy","author":"Blumencranz","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.mrrev.2024.108492_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.619817","article-title":"Pioneering BRCA1\/2 Point-of-care testing for integration of germline and tumor genetics in breast cancer risk management: a vision for the future of translational pharmacogenomics","volume":"11","author":"Mampunye","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mrrev.2024.108492_bib16","first-page":"255","article-title":"Rapid fire presentation: a rapid point-of-care test for detection of pathogenic BRCA1\/2 founder variants: pharmacogenetic evaluation of South African breast cancer patients selected by tumour molecular subtype.","author":"Kotze","year":"2021","journal-title":"Fam. Cancer"},{"key":"10.1016\/j.mrrev.2024.108492_bib17","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0960-9776(23)00163-7","article-title":"P044 A rapid point-of-care test kit for improved clinical management of patients with breast cancer and associated co-morbidities: significance of the MTHFR-homocysteine pathway","volume":"68","author":"Baatjes","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.mrrev.2024.108492_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020467","article-title":"Exome sequencing in a family with luminal-type breast cancer underpinned by variation in the methylation pathway","volume":"18","author":"van der Merwe","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mrrev.2024.108492_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5114\/pm.2016.65667","article-title":"PARP inhibitors: Review of mechanisms of action and BRCA1\/2 mutation targeting","volume":"15","author":"Dziadkowiec","year":"2016","journal-title":"Menopause Rev."},{"key":"10.1016\/j.mrrev.2024.108492_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/gcc.23014","article-title":"MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients","volume":"61","author":"Haan","year":"2022","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.mrrev.2024.108492_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2022.938561","article-title":"Implementation of multigene panel testing for breast and ovarian cancer in South Africa: a step towards excellence in oncology for the public sector","volume":"12","author":"van der Merwe","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mrrev.2024.108492_bib22","first-page":"1805","article-title":"Pharmacogenetics of aromatase inhibitors in endocrine responsive breast cancer: lessons learnt from tamoxifen and CYP2D6 genotyping","volume":"17","author":"Baatjes","year":"2017","journal-title":"Anticancer. Agents Med. Chem."},{"key":"10.1016\/j.mrrev.2024.108492_bib23","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.2174\/1381612826666200908141858","article-title":"CYP19A1 rs10046 pharmacogenetics in postmenopausal breast cancer patients treated with aromatase inhibitors: one-year follow-up","volume":"26","author":"Baatjes","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.mrrev.2024.108492_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2022.864822","article-title":"Whole exome sequencing in South Africa: Stakeholder Views on Return of Individual Research Results and Incidental Findings","volume":"13","author":"Van Der Merwe","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.mrrev.2024.108492_bib25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10689-019-00140-w","article-title":"TP53 variants of uncertain significance: increasing challenges in variant interpretation and genetic counseling","volume":"18","author":"Bittar","year":"2019","journal-title":"Fam. Cancer"},{"key":"10.1016\/j.mrrev.2024.108492_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41467-020-20188-y","article-title":"Functional studies of GWAS variants are gaining momentum","volume":"11","author":"Lichou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mrrev.2024.108492_bib27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.7196\/SAMJ.7223","article-title":"Mammaprint Pre-screen Algorithm (MPA) reduces chemotherapy in patients with early-stage breast cancer","volume":"103","author":"Grant","year":"2013","journal-title":"South Afr. Med. J."},{"key":"10.1016\/j.mrrev.2024.108492_bib28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djz230","article-title":"Stomaching Multigene Panel Testing: What to Do about CDH1?","volume":"112","author":"Stewart","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mrrev.2024.108492_bib29","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S0960-9776(21)00205-8","article-title":"Implementation of a pathology-supported genetic testing framework for return of research results to family members of deceased breast cancer patients with somatic TP53 variants","volume":"56","author":"Moremi","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.mrrev.2024.108492_bib30","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0960-9776(23)00259-X","article-title":"P142 Functional impact of a rare germline TP53 variant (NM_001126114.2, c.1018A>G, p.N340D) in a family with the Li-Fraumeni-like syndrome","volume":"68","author":"Olivier","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.mrrev.2024.108492_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-019-0690-2","article-title":"Recommendations for application of the functional evidence PS3\/BS3 criterion using the ACMG\/AMP sequence variant interpretation framework","volume":"12","author":"Brnich","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.mrrev.2024.108492_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2021.644737","article-title":"PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer","volume":"11","author":"Fusco","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mrrev.2024.108492_bib33","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mrrev.2024.108492_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/humu.24152","article-title":"Specifications of the ACMG\/AMP variant interpretation guidelines for germline TP53 variants","volume":"42","author":"Fortuno","year":"2021","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2024.108492_bib35","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/humu.20894","article-title":"Tumour characteristics as an analytical tool for classifying genetic variants of uncertain clinical significance","volume":"29","author":"Hofstra","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2024.108492_bib36","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/humu.20889","article-title":"Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes","volume":"29","author":"Greenblatt","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2024.108492_bib37","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","article-title":"Translational implications of tumor heterogeneity","volume":"21","author":"Jamal-Hanjani","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mrrev.2024.108492_bib38","unstructured":"M. Kotze, A. Okunola, A. Peeters, N. van der Merwe, R. Torrorey-Sawe, K. Baatjes, M. Conradie, J. Schneider, Integrating tumour pathology with molecular and biochemical genetics towards individualised treatment of breast cancer, in: 63rd Fac. Med. Heal. Sci. Annu. Acad. Day, Cape Town, 2019."},{"key":"10.1016\/j.mrrev.2024.108492_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mmr.2023.13023","article-title":"BRCA1 VUS: a functional analysis to differentiate pathogenic from benign variants identified in clinical diagnostic panels for breast cancer","volume":"28","author":"Louren\u00e7o","year":"2023","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.mrrev.2024.108492_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-019-0683-1","article-title":"Comparative analysis of functional assay evidence use by ClinGen variant curation expert panels","volume":"11","author":"Kanavy","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.mrrev.2024.108492_bib41","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1158\/0008-5472.CAN-07-6189","article-title":"A syngeneic variance library for functional annotation of human variation: application to BRCA2 Tomas","volume":"68","author":"Hucl","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.mrrev.2024.108492_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-022-00454-6","article-title":"Functional assessment of missense variants of uncertain significance in the cancer susceptibility gene PALB2","volume":"8","author":"Wu","year":"2022","journal-title":"Npj Breast Cancer"},{"key":"10.1016\/j.mrrev.2024.108492_bib43","first-page":"910","article-title":"2D and 3D cell cultures \u2013 a comparison of different types of cancer cell cultures","volume":"14","author":"Kapa\u0142czy\u0144ska","year":"2018","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.mrrev.2024.108492_bib44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/jmedgenet-2019-106368","article-title":"Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: Best practices in functional analysis for clinical annotation","volume":"57","author":"Monteiro","year":"2020","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.mrrev.2024.108492_bib45","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1172\/JCI70196","article-title":"BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1","volume":"126","author":"Drost","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mrrev.2024.108492_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pgen.1006236","article-title":"Interaction with PALB2 is essential for maintenance of genomic integrity by BRCA2","volume":"12","author":"Hartford","year":"2016","journal-title":"PLoS Genet"},{"key":"10.1016\/j.mrrev.2024.108492_bib47","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1093\/hmg\/ddw066","article-title":"BRCA2 minor transcript lacking exons 4-7 supports viability in mice and may account for survival of humans with a pathogenic biallelic mutation","volume":"25","author":"Thirthagiri","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mrrev.2024.108492_bib48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-cancerbio-030518-055742","article-title":"Functional genomics for cancer research: applications in vivo and in vitro","volume":"3","author":"O\u2019Loughlin","year":"2019","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.mrrev.2024.108492_bib49","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.tig.2021.08.009","article-title":"Deciphering pathogenicity of variants of uncertain significance with CRISPR-edited iPSCs","volume":"37","author":"Guo","year":"2021","journal-title":"Trends Genet"},{"key":"10.1016\/j.mrrev.2024.108492_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cells11111853","article-title":"Utility of iPSC-derived cells for disease modeling, drug development, and cell therapy","volume":"11","author":"Nicholson","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.mrrev.2024.108492_bib51","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.mrrev.2024.108492_bib52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mrrev.2024.108492_bib53","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbcan.2016.10.002","article-title":"Guidelines for the selection of functional assays to evaluate the hallmarks of cancer","volume":"1866","author":"Menyh\u00e1rt","year":"2016","journal-title":"Biochim. Biophys. Acta - Rev. Cancer"},{"key":"10.1016\/j.mrrev.2024.108492_bib54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.gheart.2017.01.009","article-title":"The role of structural bioinformatics in drug discovery by computational SNp analysis - a proposed protocol for analyzing variation at the protein level","volume":"12","author":"Brown","year":"2017","journal-title":"Glob. Heart"},{"key":"10.1016\/j.mrrev.2024.108492_bib55","first-page":"2","article-title":"Protein homology modelling and its use in South Africa","volume":"104","author":"Bishop","year":"2008","journal-title":"S. Afr. J. Sci."},{"key":"10.1016\/j.mrrev.2024.108492_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-022-01082-2","article-title":"Assessing the clinical utility of protein structural analysis in genomic variant classification: experiences from a diagnostic laboratory","volume":"14","author":"Caswell","year":"2022","journal-title":"Genome Med."},{"key":"10.1016\/j.mrrev.2024.108492_bib57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.biopha.2015.02.009","article-title":"Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer","volume":"71","author":"Subhani","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.mrrev.2024.108492_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003318","article-title":"Use of long term molecular dynamics simulation in predicting cancer associated SNPs","volume":"10","author":"Kumar","year":"2014","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.mrrev.2024.108492_bib59","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tibs.2011.01.002","article-title":"Analyzing and visualizing residue networks of protein structures","volume":"36","author":"Doncheva","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.mrrev.2024.108492_bib60","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/humu.22550","article-title":"CDKN2A unclassified variants in familial malignant melanoma: combining functional and computational approaches for their assessment","volume":"35","author":"Scaini","year":"2014","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2024.108492_bib61","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10545-017-0128-1","article-title":"The role of the clinician in the multi-omics era: are you ready?","volume":"41","author":"van Karnebeek","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.mrrev.2024.108492_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22062990","article-title":"Combined genome, transcriptome and metabolome analysis in the diagnosis of childhood cerebellar ataxia","volume":"22","author":"Ching-l\u00f3pez","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mrrev.2024.108492_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jprot.2018.02.021","article-title":"Advancing translational research and precision medicine with targeted proteomics","volume":"189","author":"Uzozie","year":"2018","journal-title":"J. Proteom."},{"key":"10.1016\/j.mrrev.2024.108492_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prca.201800113","article-title":"The case for proteomics and phospho-proteomics in personalized cancer medicine","volume":"13","author":"Doll","year":"2019","journal-title":"Proteom. - Clin. Appl."},{"key":"10.1016\/j.mrrev.2024.108492_bib65","first-page":"1","article-title":"Strategic validation of variants of uncertain significance in ECHS1 genetic testing","volume":"0","author":"Kishita","year":"2023","journal-title":"Funct. Genom."},{"key":"10.1016\/j.mrrev.2024.108492_bib66","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/s41436-020-0827-0","article-title":"Integrated analysis of metabolomic profiling and exome data supplements sequence variant interpretation, classification, and diagnosis","volume":"22","author":"Alaimo","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.mrrev.2024.108492_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/epigenomes6030021","article-title":"Epigenomic approaches for the diagnosis of rare diseases","volume":"6","author":"Martinez-Delgado","year":"2022","journal-title":"Epigenomes"},{"key":"10.1016\/j.mrrev.2024.108492_bib68","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41436-020-01096-4","article-title":"Clinical epigenomics: genome-wide DNA methylation analysis for the diagnosis of Mendelian disorders","volume":"23","author":"Sadikovic","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.mrrev.2024.108492_bib69","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/fft2.44","article-title":"Guidelines for cell viability assays","volume":"1","author":"Kamiloglu","year":"2020","journal-title":"Food Front"},{"key":"10.1016\/j.mrrev.2024.108492_bib70","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1002\/humu.24462","article-title":"A calibrated cell-based functional assay to aid classification of MLH1 DNA mismatch repair gene variants","volume":"43","author":"Rath","year":"2022","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2024.108492_bib71","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.intimp.2016.10.019","article-title":"Flow cytometric analysis of T lymphocyte proliferation in vivo by EdU incorporation","volume":"41","author":"Sun","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.mrrev.2024.108492_bib72","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nprot.2009.143","article-title":"Expression, purification and use of recombinant annexin V for the detection of apoptotic cells","volume":"4","author":"Logue","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.mrrev.2024.108492_bib73","article-title":"Assaying cell cycle status using flow cytometry","volume":"2015","author":"Kim","year":"2015","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"10.1016\/j.mrrev.2024.108492_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcell.2019.00107","article-title":"In vitro cell migration, invasion, and adhesion assays: From cell imaging to data analysis","volume":"7","author":"Pijuan","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mrrev.2024.108492_bib75","first-page":"1","article-title":"In vitro cell migration and invasion assays","author":"Justus","year":"2014","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.mrrev.2024.108492_bib76","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bbrc.2013.11.134","article-title":"Somatic mutational analysis of FAK in breast cancer: A novel gain-of-function mutation due to deletion of exon 33","volume":"443","author":"Fang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.mrrev.2024.108492_bib77","first-page":"1","article-title":"Identification of recurrent variants in BRCA1 and BRCA2 across multiple cancers in the Chinese population","volume":"2020","author":"Jiang","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.mrrev.2024.108492_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.01543","article-title":"Establishment of a 3D Co-culture With MDA-MB-231 Breast Cancer Cell Line and Patient-Derived Immune Cells for Application in the Development of Immunotherapies","volume":"10","author":"Saraiva","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mrrev.2024.108492_bib79","first-page":"1","article-title":"Endothelial cell tube formation assay for the in vitro study of angiogenesis","volume":"10","author":"DeCicco-Skinner","year":"2014","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.mrrev.2024.108492_bib80","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1016\/j.stemcr.2022.10.014","article-title":"Patient-specific and gene-corrected induced pluripotent stem cell-derived endothelial cells elucidate single-cell phenotype of pulmonary veno-occlusive disease","volume":"17","author":"Ma","year":"2022","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.mrrev.2024.108492_bib81","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1093\/hmg\/ddab219","article-title":"Linking genome variants to disease: scalable approaches to test the functional impact of human mutations","volume":"30","author":"Findlay","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mrrev.2024.108492_bib82","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajhg.2017.07.014","article-title":"Variant Interpretation: functional assays to the rescue","volume":"101","author":"Starita","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.mrrev.2024.108492_bib83","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.ajhg.2021.11.001","article-title":"Closing the gap: systematic integration of multiplexed functional data resolves variants of uncertain significance in BRCA1, TP53, and PTEN","volume":"108","author":"Fayer","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.mrrev.2024.108492_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11689-022-09461-x","article-title":"Focus on your locus with a massively parallel reporter assay","volume":"14","author":"McAfee","year":"2022","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.mrrev.2024.108492_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2023.1087267","article-title":"Deep mutational scanning: a versatile tool in systematically mapping genotypes to phenotypes","volume":"14","author":"Wei","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.mrrev.2024.108492_bib86","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ajhg.2020.12.003","article-title":"Massively parallel functional testing of MSH2 missense variants conferring Lynch syndrome risk","volume":"108","author":"Jia","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.mrrev.2024.108492_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-022-02839-z","article-title":"Saturation-scale functional evidence supports clinical variant interpretation in Lynch syndrome","volume":"23","author":"Scott","year":"2022","journal-title":"Genome Biol."},{"key":"10.1016\/j.mrrev.2024.108492_bib88","first-page":"297","article-title":"Reducing uncertainty in genetic testing with saturation genome editing","volume":"34","author":"Dace","year":"2022","journal-title":"Med. Genet"},{"key":"10.1016\/j.mrrev.2024.108492_bib89","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","article-title":"Accurate classification of BRCA1 variants with saturation genome genome editing","volume":"562","author":"Findlay","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.mrrev.2024.108492_bib90","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10689-020-00202-4","article-title":"Clinical phenotypes combined with saturation genome editing identifying the pathogenicity of BRCA1 variants of uncertain significance in breast cancer","volume":"20","author":"Wan","year":"2021","journal-title":"Fam. Cancer"},{"key":"10.1016\/j.mrrev.2024.108492_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-39796-w","article-title":"Selecting variants of unknown significance through network-based gene-association significantly improves risk prediction for disease-control cohorts","volume":"9","author":"Oulas","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mrrev.2024.108492_bib92","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ajhg.2021.03.003","article-title":"Opportunities and challenges for the computational interpretation of rare variation in clinically important genes","volume":"108","author":"McInnes","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.mrrev.2024.108492_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/bib\/bbad479","article-title":"A review of genetic variant databases and machine learning tools for predicting the pathogenicity of breast cancer","volume":"25","author":"Ahmad","year":"2023","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.mrrev.2024.108492_bib94","first-page":"1199","article-title":"T. v O. Hansen, F.J. Couch, M.P.G. Vreeswijk, Functional assays for analysis of variants of uncertain significance in BRCA2","volume":"18","author":"Guidugli","year":"2014","journal-title":"Hum. Mutat."}],"container-title":["Mutation Research - Reviews in Mutation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138357422400005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138357422400005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T22:23:00Z","timestamp":1716502980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S138357422400005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":94,"alternative-id":["S138357422400005X"],"URL":"https:\/\/doi.org\/10.1016\/j.mrrev.2024.108492","relation":{},"ISSN":["1383-5742"],"issn-type":[{"value":"1383-5742","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incorporating functional genomics into the pathology-supported genetic testing framework implemented in South Africa: A future view of precision medicine for breast carcinomas","name":"articletitle","label":"Article Title"},{"value":"Mutation Research - Reviews in Mutation Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mrrev.2024.108492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108492"}}